Login
Pfizer buys ResApp for $100m
Digital health company ResApp has entered into a binding scheme of arrangement with Pfizer, in a deal worth $100 million.
Lauren Croft
Firm: DLA Piper (ResApp Health Limited)
Value: $100 million approx.
Area: M&A
Key players: The DLA Piper team was led by partners James Nicholls, Greg Bodulovic and Fleur Gibbons with assistance from Kirsty Hall, Chantal Encavey, Kit Lloyd, Emily Donley and Joshua Scoles.
Deal significance: ResApp will also enter into a research, development and license agreement, wherein Pfizer and ResApp will collaborate on the research and development of products in the field of COVID-19.
Commenting on the deal, Mr Nicholls said: “An interconnected team across public M&A, anti-trust and IP was required to deliver a clear understanding of the value proportion at short notice. DLA’s teams, as always, overperformed and we were able to meet the client’s requirements. Looking forward to seeing how this transaction develops.”
Lauren Croft
Lauren is a journalist at Lawyers Weekly and graduated with a Bachelor of Journalism from Macleay College. Prior to joining Lawyers Weekly, she worked as a trade journalist for media and travel industry publications and Travel Weekly. Originally born in England, Lauren enjoys trying new bars and restaurants, attending music festivals and travelling. She is also a keen snowboarder and pre-pandemic, spent a season living in a French ski resort.
